金斯瑞生物科技：蓬勃根据与礼新医药科技的许可协议收到新付款

Core Insights - Kingsray Biotechnology (01548) announced the receipt of approximately RMB 480 million (around USD 67.5 million, net of withholding tax) as a new payment under the restated and amended licensing agreement [1] - This payment represents the second tranche of sublicensing revenue related to the licensed anti-PD-1 single-domain antibody, which is utilized in the development of the investigational PD-1/VEGF bispecific antibody LM-299, now approved for new drug clinical research [1] - As of October 14, 2025, Kingsray has cumulatively received approximately RMB 2 billion (around USD 284 million, net of withholding tax) under the same licensing agreement [1] - The incoming funds will further enhance Kingsray's cash reserves and support new molecular discovery and development [1]